Phase 2 N=56 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Recurrent Uterine Sarcoma · Stage III Uterine Sarcoma · Stage IV Uterine Sarcoma
Primary: Objective Overall Response Rate — 2; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Diet and Physical Activity in Uterine Cancer Survivors
Endometrial Neoplasms
Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants
Phase 2 N=42 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response — 11.8 percentage
Phase 2 N=55 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
Sarcoma
Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants
Phase 2 N=26 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants
Phase 2 N=20 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Sarcoma
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 2 N=28 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants
Phase 2 N=22 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants
Phase 2 N=61 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Phase 2 N=35 A Study of Nivolumab in Selected Uterine Cancer Patients
Uterine Cancer · Endometrial Carcinoma · Carcinosarcoma
Primary: Progression-Free Survival — 64.7 percentage of patients
Phase 2 N=81 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=30 A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
Uterine Cancer
Primary: 3-year Overall Survival — 17 partipants
Phase 2 N=23 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Mixed Tumor, Mullerian
Primary: Number of Participants With Overall Response — 8 participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Early Phase 1 N=100 Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion
Endometrial Cancer
Primary: Percentage of Participants With Positive Predictive Value and Negative Predictive Value From Fluorescein Visualization — 71; 100; 85; 90 percentage of participants
Phase 2 N=47 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Phase 2 N=20 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
N/A N=22 Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix
Uterine Cancer · Cervical Cancer
Primary: Dosimetric Comparison of Proton Beam Treatment With 3-dimensional Conformal Radiation Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT) — 455.0; 149.0…
Phase 2 N=26 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Leiomyosarcoma
Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants
Phase 2 N=19 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Objective Response Rate (PR or CR) — 0 percentage of evalubale patients
Phase 2 N=16 ZW25 in Women With Endometrial Cancers
Endometrial Cancer · Carcinosarcoma
Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants
Phase 2 N=20 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Mixed Mullerian Tumors of the Uterus
Primary: Chemotherapy Completion Rate — 100 percentage of participants